Computational Characterization of Ceftriaxone and Novel Compounds in Opioid Use Disorder: Network Pharmacology, Molecular Docking, and Molecular Dynamics Simulations
Opioid use disorder (OUD) is a global issue characterized by compulsive opioid use and is linked to significant morbidity and mortality. Ceftriaxone has been investigated for its potential neuroprotective and immunomodulatory effects; however, its mechanisms in opioid dependence remain unclear. This study employed a network pharmacological approach to explore the potential molecular target of ceftriaxone and related signaling pathways in OUD. Targets were identified based on a comparative toxicogenomics database, SwissTargetPrediction, complemented by PharmMapper for ceftriaxone and GeneCards and Gene Expression Omnibus for OUD. Overlapping targets were identified using Venn diagrams and analyzed via the STRING platform to construct a protein–protein interaction network. Biological insights were sourced from the DAVID database, and Gene Ontology and KEGG pathway enrichment evaluated the biological significance of the target genes using Metascape. Molecular docking was performed using AutoDock Vina (version 1.1.1) for ceftriaxone, its analogs, and other GLT-1 modulators: MC-100093, MC-350012, MC-350013, and MC-290401. A total of 10 overlapping genes (IL-1β, TNF, ALB, EGFR, ESR1, CDK5, MME, SLC1A2, EPO, and SRC) were identified with multiple biological functions and signaling pathways. Molecular docking predicted that the novel GLT-1 modulator, MC-350013, exhibited favorable docking scores toward several prioritized proteins, particularly ESR1, EGFR, IL-1β, and ALB. Molecule 13 also demonstrated favorable docking scores for the selected proteins. Molecular dynamics simulations characterized the interaction behavior of the novel GLT-1 modulator, MC-350012 and MC-350013. Although ceftriaxone showed stronger hydrogen-bonding interactions, MC-350012 and MC-350013 showed favorable predicted interaction profiles with IL-1β and ESR1. Collectively, these computational findings may suggest MC-350012 and MC-350013 as candidates for further experimental investigation based on their predicted interactions with key OUD-related targets.
Authors
- Magid A. Abou-Gharbia (ORCID: https://orcid.org/0000-0001-7524-6011)
- Faizul Azam (ORCID: https://orcid.org/0000-0002-2927-8167)
- Qamraa Hamad Alqahtani (ORCID: https://orcid.org/0000-0002-6538-9710)
- Wayne E. Childers (ORCID: https://orcid.org/0000-0003-0527-3684)
- Abdullah F. Alasmari (ORCID: https://orcid.org/0000-0001-7569-4287)
- Youssef Sari (ORCID: https://orcid.org/0000-0002-6761-9786)
- Rawan Saleh Alsikhan (ORCID: https://orcid.org/0000-0003-4612-604X)
- Mohammed M. Alshehri (ORCID: https://orcid.org/0000-0002-2041-4695)
- Thikra Algahtani
- Fawaz F. Alasmari (ORCID: https://orcid.org/0000-0003-2382-5892)
- Sarah T. Binakeel
- Hala H. Alrefashy
Institutions
- Qassim University (SA)
- King's College London (GB)
- King Saud University (SA)
- Temple University (US)
- University of Toledo (US)
Publication Details
- Journal
- Current Issues in Molecular Biology
- Published
- 2026-11-16
- DOI
- https://doi.org/10.3390/cimb48111231
- Primary Topic
- Computational Drug Discovery Methods
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- King Saud University